Why generic Ozempic could soon become a lot cheaper in Quebec

Novo Nordisk's semaglutide exclusivity in Canada expired Jan. 4, 2026, prompting at least three companies to file for generic production and forecasts that Quebec prices for GLP-1 drugs could fall up to 75% (from about CAD 400/month to ~CAD 100/month). More than one million Canadians currently use GLP-1 drugs and Quebec officials estimate roughly 48% of the province could qualify; while generics and lower prices may materially expand demand and reduce Novo Nordisk's Canadian pricing power, access may still be constrained by public payer coverage limits and physician capacity for monitoring.

Analysis

Market structure: Quebec’s semaglutide patent expiry shifts pricing power from Novo Nordisk (NVO) to generics, directly benefiting Canadian generic manufacturers, wholesalers and retail pharmacies while compressing Novo’s Canadian semaglutide margins. Expect list-price falls up to ~75% and a signficant uptake ramp (plausible doubling of Canadian users from ~1M to 2–2.5M within 12–24 months) but limited near-term global revenue impact because Canada is a low-single-digit percent of Novo’s total sales.

Risk assessment: Key tail risks are provincial reimbursement reversals, stricter safety/monitoring mandates, and manufacturing/biosimilar regulatory delays that could push generic launches from weeks to 3–12+ months. Immediate (days) catalysts are Health Canada approvals; short-term (weeks–months) are RAMQ policy shifts and supply announcements; long-term (quarters–years) is global patent erosion and pricing parity pressure. Hidden dependencies include physician capacity and follow-up requirements that can cap real-world uptake.

Trade implications: Implement event-driven, size-constrained trades: (a) tactical short bias on NVO focused on Canadian revenue risk (1–2% portfolio via 3–6 month put or put spread to limit premium spend); (b) long exposure to high-quality generics/wholesalers (1–3% positions) executed after confirmed Health Canada approvals; (c) pair trade long approved generic names vs short NVO to isolate regulatory outcome risk. Rotate out of single-product branded small-cap biotechs into diversified pharma/wholesale names while hedging with options.

Contrarian angles: The market may over-penalize NVO—semaglutide is a biologic with complex manufacturing and regulatory hurdles for biosimilars, so practical generic competition could be delayed 3–12 months. Canada’s market size limits structural earnings damage (<mid-single-digit % to global revenue), and lower prices could expand indications and volumes that partially offset unit-price erosion. Size positions small, event-locked, and reprice on approvals or RAMQ coverage changes.

Key Decisions for Investors

• Establish a tactical 1–2% portfolio short on NVO via a 3–6 month put spread to capture near-term Canadian revenue/psychology risk; size tight to limit exposure given global revenue concentration.
• Allocate 1–3% to high-quality generics/wholesalers (enter only after Health Canada approval announcements for Canadian semaglutide generics—buy outright or 6-month calls) to capture initial market share gains; set stop-loss at -20% from entry.
• Execute a pair trade: long approved generic manufacturer (1% position) and short NVO (1% position) after Health Canada publishes approval list (monitor daily for announcements over next 30 days); rebalance at 30–90 days post-approval.
• Reduce exposure by 2–5% to single-product branded biotech holdings with similar patent cliffs; redeploy to diversified pharma or managed-care/wholesaler names over the next 30–90 days to lower idiosyncratic patent risk.
• Monitor three triggers over next 60 days and act: (a) Health Canada generic approvals (buy long leg), (b) RAMQ policy change to expand coverage (increase long generic/wholesaler sizing if positive), (c) formal manufacturing/quality delays announced by generics (de-risk by widening short NVO hedge).